Lexeo Raises $100m To Advance CNS Candidates, Validate Cardiac Gene Therapies
Start-Up Has Brought In $185m In Less Than A Year
The company, which has treatments in the clinic for CLN2 Batten disease and APOE4-associated Alzheimer’s disease, is developing AAV-mediated gene therapies designed for safer outcomes.
You may also be interested in...
Public Company Edition: Lexeo raised $100m to advance its genetic medicines. Also, Blue Owl Capital acquired funds managed by Cowen Healthcare Investments, gaining about $1bn in life science assets, BMS priced $4.5bn in notes to fund its Mirati purchase and Viridian raised $185m in a private placement.
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
Since becoming CEO of Lexeo a year before its launch, R. Nolan Townsend has steered the company from strength to strength, expanding its pipeline from three to eight novel therapeutics and ultimately developing therapeutics for a future where gene therapy can cut healthcare costs.